Vaxcyte (PCVX) On Tighter Phase 3 Timing And New Hires Looks Undervalued

Vaxcyte (PCVX) has given investors two fresh data points to consider. The company provided more specific timing for key VAX-31 Phase 3 readouts and added senior leaders for medical and legal oversight.

Recent trading has been choppy, with a 1-day share price return of 0.97% and a 7-day share price decline of 2.76%. However, Vaxcyte’s 90-day share price return of 25.31% alongside a 1-year total shareholder return of 84.86% points to momentum that has been building rather than fading as investors digest the tighter VAX-31 data timeline and senior hires.

Capitalize on the momentum around Vaxcyte’s pipeline by sizing it up alongside hand-picked peers using our 16 high quality undiscovered gems, which pair strong fundamentals with under-the-radar profiles.

Vaxcyte now trades at a steep discount to both analyst targets and intrinsic value estimates after its recent run. Is that a bargain or a clear signal that the market’s caution around a loss-making vaccine developer is warranted?

Most Popular Narrative: 45.4% Undervalued

Against Vaxcyte’s last close of $59.47, the most followed narrative pegs fair value at $109, using a detailed earnings and discount rate framework.

Expanded adult pneumococcal vaccination recommendations in the US and increasing adoption of adult PCV programs internationally are enlarging the addressable market for higher valency vaccines such as VAX-31. This directly relates to potential future revenue scale.

Read the complete narrative. Read the complete narrative.

Want to understand why this framework lands on a much higher value for Vaxcyte than today’s share price? The core assumptions blend rapid top line expansion, eventual margin uplift and a rich earnings multiple that leans heavily on long dated cash flows.

Result: Fair Value of $109 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the bullish Vaxcyte narrative leans heavily on OPUS trial outcomes and assumes complex vaccine manufacturing ramps smoothly. Both of these factors could disappoint and reset expectations.

Find out about the key risks to this Vaxcyte narrative.

Another View on Vaxcyte’s Valuation

That 45.4% analyst discount is one story. A different one comes from the P/B ratio, where Vaxcyte trades at 3.2x book value compared with 2.3x for the wider US Biotechs group and 11.3x for peers. This points to both valuation risk and potential upside if sentiment shifts.

To see what the numbers say about this price in a simple ratio framework, and how they might adjust if expectations change, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The Vaxcyte story has sent mixed messages so far. Consider the information carefully while it is still fresh and weigh both sides by checking the 2 key rewards and 2 important warning signs.

Looking for more ideas beyond Vaxcyte?

Do not stop at Vaxcyte. The best opportunities often sit just outside the obvious picks, and a few minutes of focused searching can change your watchlist.

• Target cash rich businesses with sensible valuations by scanning our list of solid balance sheet and fundamentals (23 results). This pairs robust finances with resilient fundamentals.
• Hunt for potential mispricings using the 31 high quality undervalued stocks and see which companies combine healthy balance sheets with compressed multiples.
• Prioritize resilience first by using the 11 resilient stocks with low risk scores so you can focus on ideas where the risk score stays on the lower side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com